{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:27:40Z","timestamp":1793147260231,"version":"4.5.0"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"14","license":[{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic inflammation and joint destruction. Iguratimod (IGU) is a novel conventional synthetic disease-modifying antirheumatic drugs (csDMARD) with good efficacy and safety for the treatment of active RA in China and Japan. However, the long-term effects of IGU on the progression of bone destruction or radiographic progression in patients with active RA remain unknown. We aimed to investigate the efficacy and safety of iguratimod (IGU), a combination of methotrexate (MTX) and IGU, and IGU in patients with active rheumatoid arthritis (RA) who were na\u00efve to MTX.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This multicenter, double-blind, randomized, non-inferiority clinical trial was conducted at 28 centers for over 52 weeks in China. In total, 911 patients were randomized (1:1:1) to receive MTX monotherapy (10\u201315 mg weekly, <jats:italic toggle=\"yes\">n<\/jats:italic> = 293), IGU monotherapy (25 mg twice daily, <jats:italic toggle=\"yes\">n<\/jats:italic> = 297), or IGU + MTX (10\u201315 mg weekly for MTX and 25 mg twice daily for IGU, <jats:italic toggle=\"yes\">n<\/jats:italic> = 305) for 52 weeks. The patients\u2019 clinical characteristics, Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), disease activity score in 28 joints-C-reactive protein (DAS28-CRP) level, and disease activity score in 28 joints-erythrocyte sedimentation rate (DAS28-ESR) were assessed at baseline. The primary endpoints were the proportion of patients with \u226520% improvement according to the American College of Rheumatology (ACR20) response and changes in the van der Heijde-modified total Sharp score (vdH-mTSS) at week 52.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The proportions of patients achieving an ACR20 response at week 52 were 77.44%, 77.05 %, and 65.87% for IGU monotherapy, IGU + MTX, and MTX monotherapy, respectively. The non-inferiority of IGU monotherapy to MTX monotherapy was established with the ACR20 (11.57%; 95% confidence interval [CI], 4.35\u201318.79%; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt;0.001) and vdH-mTSS (\u22120.37; 95% CI, \u22121.22\u20130.47; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.022). IGU monotherapy was also superior to MTX monotherapy in terms of ACR20 (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.002) but not the vdH-mTSS. The superiority of IGU + MTX over MTX monotherapy was confirmed in terms of the ACR20 (11.18%; 95% CI, 3.99\u201318.37%; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.003), but not in the vdH-mTSS (\u22120.68; 95% CI, \u22121.46\u20130.11; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.091). However, the difference in the incidence rates of adverse events was not statistically significant.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>IGU monotherapy\/IGU + MTX showed a more favorable clinical response than did MTX monotherapy. IGU may have some clinical benefits over MTX in terms of radiographic progression, implying that IGU may be considered as an initial therapeutic option for patients with active RA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial Registration:<\/jats:title>\n            <jats:p>\n                                 https:\/\/classic.clinicaltrials.gov\/, NCT01548001.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cm9.0000000000003200","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T05:02:17Z","timestamp":1721970137000},"page":"1705-1713","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["The SMILE study: Study of long-term methotrexate and iguratimod combination therapy in early rheumatoid arthritis"],"prefix":"10.1097","volume":"138","author":[{"given":"Fang","family":"Du","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai 200001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai 200001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Teng","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai 200001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangjing","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai 200001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai 200001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai 200001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqian","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Radiology, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai 200001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Radiology, Southeast University Zhongda Hospital, Nanjing, Jiangsu 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai 200001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunde","family":"Bao","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai 200001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the SMILE Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,7,26]]},"reference":[{"key":"R1-20250720","first-page":"242","article-title":"2018 Chinese guideline for the diagnosis and treatment of rheumatoid arthritis (in Chinese)","volume":"57","author":"Chinese Rheumatology","year":"2018","journal-title":"Chin J Intern Med"},{"key":"R2-20250720","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: A review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"key":"R3-20250720","first-page":"455","article-title":"Rheumatoid arthritis: Common questions about diagnosis and management","volume":"97","author":"Wasserman","year":"2018","journal-title":"Am Fam Physician"},{"key":"R4-20250720","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.pop.2018.02.010","article-title":"Early diagnosis and treatment of rheumatoid arthritis","volume":"45","author":"Littlejohn","year":"2018","journal-title":"Prim Care"},{"key":"R5-20250720","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1097\/CM9.0000000000002336","article-title":"Efficacy, safety, and cost-effectiveness of triple therapy in preventing relapse in rheumatoid arthritis: A randomized controlled trial (ESCoRT study)","volume":"135","author":"Zhao","year":"2022","journal-title":"Chin Med J"},{"key":"R6-20250720","article-title":"Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial","volume":"354","author":"Haavardsholm","year":"2016","journal-title":"BMJ"},{"key":"R7-20250720","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jama.2018.21362","article-title":"Effect of magnetic resonance imaging vs conventional treat-to-target strategies on disease activity remission and radiographic progression in rheumatoid arthritis: The IMAGINE-RA randomized clinical trial","volume":"321","author":"M\u00f8ller-Bisgaard","year":"2019","journal-title":"JAMA"},{"key":"R8-20250720","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nrrheum.2013.73","article-title":"Musculoskeletal ultrasonography in patients with rheumatoid arthritis","volume":"9","author":"Ohrndorf","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"R9-20250720","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"R10-20250720","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1136\/annrheumdis-2016-210602","article-title":"2016 update of the EULAR recommendations for the management of early arthritis","volume":"76","author":"Combe","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R11-20250720","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R12-20250720","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/ard.2008.102822","article-title":"Methotrexate: The gold standard without standardisation","volume":"68","author":"Kay","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R13-20250720","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/14397595.2018.1472358","article-title":"Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis","volume":"29","author":"Kameda","year":"2019","journal-title":"Mod Rheumatol"},{"key":"R14-20250720","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/s10165-006-0542-y","article-title":"Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study","volume":"17","author":"Hara","year":"2007","journal-title":"Mod Rheumatol"},{"key":"R15-20250720","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/art.24643","article-title":"Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate","volume":"61","author":"Lu","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R16-20250720","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/00029330-200804010-00008","article-title":"Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: A double blind, randomized, placebo-controlled and multicenter trial","volume":"121","author":"Lu","year":"2008","journal-title":"Chin Med J"},{"key":"R17-20250720","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3389\/fphar.2020.00073","article-title":"Iguratimod as a new drug for rheumatoid arthritis: Current landscape","volume":"11","author":"Xie","year":"2020","journal-title":"Front Pharmacol"},{"key":"R18-20250720","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/1756-185X.13513","article-title":"2018 update of the APLAR recommendations for treatment of rheumatoid arthritis","volume":"22","author":"Lau","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"R19-20250720","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.3899\/jrheum.171176","article-title":"Sex-associated treatment differences and their outcomes in rheumatoid arthritis: Results from the METEOR register","volume":"45","author":"Bergstra","year":"2018","journal-title":"J Rheumatol"},{"key":"R20-20250720","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"R21-20250720","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"5","key":"R22-20250720","first-page":"S100","article-title":"The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): A review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"R23-20250720","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","article-title":"A simplified disease activity index for rheumatoid arthritis for use in clinical practice","volume":"42","author":"Smolen","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"R24-20250720","doi-asserted-by":"crossref","first-page":"R796","DOI":"10.1186\/ar1740","article-title":"Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: Validation of a clinical activity score","volume":"7","author":"Aletaha","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"R25-20250720","first-page":"261","article-title":"How to read radiographs according to the Sharp\/van der Heijde method","volume":"27","author":"van der Heijde","year":"2000","journal-title":"J Rheumatol"},{"key":"R26-20250720","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/art.10181","article-title":"How to report radiographic data in randomized clinical trials in rheumatoid arthritis: Guidelines from a roundtable discussion","volume":"47","author":"van der Heijde","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R27-20250720","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis Rheum"},{"key":"R28-20250720","first-page":"789","article-title":"The dimensions of health outcomes: The health assessment questionnaire, disability and pain scales","volume":"9","author":"Fries","year":"1982","journal-title":"J Rheumatol"},{"key":"R29-20250720","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/BOR.0b013e328329c79d","article-title":"An update on methotrexate","volume":"21","author":"Braun","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"R30-20250720","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R31-20250720","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3109\/s10165-012-0724-8","article-title":"Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: A randomized, double-blind, placebo-controlled trial","volume":"23","author":"Ishiguro","year":"2013","journal-title":"Mod Rheumatol"},{"key":"R32-20250720","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3109\/14397595.2013.843756","article-title":"Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: An open-label extension of a randomized, double-blind, placebo-controlled trial","volume":"24","author":"Hara","year":"2014","journal-title":"Mod Rheumatol"},{"key":"R33-20250720","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.molimm.2017.10.008","article-title":"Iguratimod ameliorates inflammatory responses by modulating the Th17\/Treg paradigm in dextran sulphate sodium-induced murine colitis","volume":"93","author":"Jiang","year":"2018","journal-title":"Mol Immunol"},{"key":"R34-20250720","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/rheumatology\/keg381","article-title":"Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice","volume":"42","author":"Tanaka","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"R35-20250720","doi-asserted-by":"crossref","first-page":"356040","DOI":"10.1155\/2015\/356040","article-title":"Regulatory effect of iguratimod on the balance of Th subsets and inhibition of inflammatory cytokines in patients with rheumatoid arthritis","volume":"2015","author":"Xu","year":"2015","journal-title":"Mediators Inflamm"},{"key":"R36-20250720","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13075-019-1874-2","article-title":"Iguratimod represses B cell terminal differentiation linked with the inhibition of PKC\/EGR1 axis","volume":"21","author":"Ye","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"R37-20250720","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/PL00000291","article-title":"An anti-rheumatic agent T-614 inhibits NF-kappaB activation in LPS- and TNF-alpha-stimulated THP-1 cells without interfering with IkappaBalpha degradation","volume":"51","author":"Aikawa","year":"2002","journal-title":"Inflamm Res"},{"key":"R38-20250720","first-page":"2591","article-title":"Inhibitory effect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factor-kappaB activation in cultured human synovial cells","volume":"28","author":"Kohno","year":"2001","journal-title":"J Rheumatol"},{"key":"R39-20250720","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.4049\/jimmunol.1300832","article-title":"A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide","volume":"191","author":"Luo","year":"2013","journal-title":"J Immunol"},{"key":"R40-20250720","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1097\/CM9.0000000000002678","article-title":"Osteoimmunology research in rheumatoid arthritis: From single-cell omics approach","volume":"136","author":"Hu","year":"2023","journal-title":"Chin Med J"},{"key":"R41-20250720","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1080\/14397595.2018.1481565","article-title":"Iguratimod, a synthetic disease modifying anti-rheumatic drug inhibiting the activation of NF-kappaB and production of RANKL: Its efficacy, radiographic changes, safety and predictors over two years\u2019 treatment for Japanese rheumatoid arthritis patients","volume":"29","author":"Ishikawa","year":"2019","journal-title":"Mod Rheumatol"},{"key":"R42-20250720","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/14397595.2016.1265695","article-title":"Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: Interim analysis of a post-marketing surveillance study of 2679 patients in Japan","volume":"27","author":"Mimori","year":"2017","journal-title":"Mod Rheumatol"},{"key":"R43-20250720","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1080\/14397595.2018.1460230","article-title":"Safety and effectiveness of iguratimod in patients with rheumatoid arthritis: Final report of a 52-week, multicenter postmarketing surveillance study","volume":"29","author":"Mimori","year":"2019","journal-title":"Mod Rheumatol"},{"key":"R44-20250720","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1358\/dot.2012.48.9.1855758","article-title":"Iguratimod: A new disease-modifying antirheumatic drug","volume":"48","author":"Mucke","year":"2012","journal-title":"Drugs Today (Barc)"},{"key":"R45-20250720","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/14397595.2018.1510879","article-title":"The three-year efficacy of iguratimod in clinical daily practice in patients with rheumatoid arthritis","volume":"29","author":"Suto","year":"2019","journal-title":"Mod Rheumatol"},{"key":"R46-20250720","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2217\/pgs-2017-0162","article-title":"Genetic predictors of efficacy and toxicity of iguratimod in patients with rheumatoid arthritis","volume":"19","author":"Xiao","year":"2018","journal-title":"Pharmacogenomics"},{"key":"R47-20250720","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.intimp.2016.03.038","article-title":"Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-kappaB and MAPK pathways","volume":"35","author":"Gan","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"R48-20250720","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s10067-017-3668-8","article-title":"Effects of iguratimod on the levels of circulating regulators of bone remodeling and bone remodeling markers in patients with rheumatoid arthritis","volume":"36","author":"Wang","year":"2017","journal-title":"Clin Rheumatol"},{"key":"R49-20250720","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/0049-0172(90)90060-S","article-title":"Methotrexate: Mechanism of action in rheumatoid arthritis","volume":"20","author":"Segal","year":"1990","journal-title":"Semin Arthritis Rheum"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003200","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T04:00:51Z","timestamp":1752984051000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,26]]},"references-count":49,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000003200","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,26]]},"assertion":[{"value":"2023-10-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}